Abstract The 17-oximino-5-androsten-3β-yl esters (10a–10j) were synthesized from commercially available (25 R)-5-Spirosten-3β-ol (Diosgenin)(4) as starting material. The synthesized compounds were evaluated for their antiproliferative activity against prostate specific cancer cell line DU-145, acute toxicity, and effect on serum androgen level and were compared with Finasteride used as positive control. Some of the compounds exhibited ...